Giving a Voice to Silent Endometriosis
Over 300 fertility centers around the US and globally depend on Cicero Diagnostics to help them with their most challenging patients
Menu
Over 300 fertility centers around the US and globally depend on Cicero Diagnostics to help them with their most challenging patients
ReceptivaDx represents a new generation of testing to detect defects on the uterine lining responsible for unexplained infertility, implantation failure and recurrent pregnancy loss. Using proprietary biochemical markers, endometrial tissue (obtained via biopsy) can now be analyzed without the need for invasive surgery to detect inflammation most often associated with asymptomatic endometriosis.
BCL6, the primary marker of the ReceptivaDx test has been demonstrated to have 93% sensitivity and 96% specificity in the detection of endometriosis. The condition of endometriosis is believed to be the biggest culprit behind the majority of unexplained infertility cases after all other male and female factors have been ruled out.
The declining use of laparoscopy in the last 15 years has made the availability of the BCL6 marker more important than ever. The ability to measure BCL6 via the ReceptivaDx test provides a reliable, affordable and much less invasive method for detection, providing new hope and new treatment pathways to pregnancy in the most challenging fertility cases.
In addition to being recognized a marker of inflammation linked to endometriosis, BCL6 has also been found to play a key role in progesterone resistance. The hormone progesterone is vital in pregnancy to create a safe environment for a developing embryo. Since BCL6 inhibits progesterone when over-expressed, this causes a less viable endometrial environment and the inability to protect the developing embryo throughout pregnancy.
To learn more about ReceptivaDx, click the button below.
Extensive published clinical data is available to support the use of ReceptivaDx in the clinical setting for assistance in unexplained infertility.
Click Here for Full Publication List
Cicero Diagnostics has ongoing research via an NIH Commercial Grant Awarded in 2019 to further evaluate and develop testing mechanisms related to markers associated with endometriosis, unexplained infertility, failed IVF and recurrent pregnancy loss.
Dept of Ob-Gyn – Reproductive Medicine Winston Salem, NC
Department of Reproductive Medicine Palo Alto, CA
Dept of Ob-Gyn Reproductive Medicine Raleigh, NC
Clemson, SC
In 2019, Cicero Diagnostics established a collaborative network of high-volume referring clients across the US. As part of our “Shared Experience Program” , these participating centers will work with Cicero Diagnostics to provide treatment and outcome data based on patients testing positive for ReceptivaDx markers. Cicero Diagnostics published its first set of outcomes data on over 140 patients from seven major centers in April of 2020. This data supported the previous published studies showing the success of the ReceptivaDx markers. By the end of 2021, Cicero Diagnostics had performed testing on over 10,000 patients representing 350 centers worldwide.
Chris Jackson has been in diagnostic lab testing for over 30 years focusing on health care sales and marketing. Mr. Jackson has launched over 35 products during his career, with the majority in the field of women’s health & reproductive medicine.
From 1998-2006, Chris was National Sales Director of US sales for Adeza biomedical. Adeza’s key product was an assay known as Fetal Fibronectin, used by OBGYN’s to identify women at risk of preterm birth. He took the company from $2M in sales in 1998 to $45M in 2006. In 2004, the company had a successful IPO and was eventually purchased but Cytech (now Hologic) in 2007. From his experience at Adeza and his deep understanding of Women’s Health, Chris started Cicero Diagnostics after negotiating exclusive rights to a unique biomarker highly associated with endometriosis and infertility held by the University of North Carolina. Since Cicero Diagnostics launch in 2017, the company has seen explosive growth in test use, research publications and a million dollar NIH small business (SBIR) grant. In addition, ReceptivaDx’s growing social media presence has provided access to educational information on the value of the test across multiple channels worldwide.
Mr. Angress has over 30 years experience in diagnostic medicine focused on commercialization and operations . He has overseen multiple labs in various executive capacities including business development, marketing, customer service, product management, and operations. His breadth of knowledge in women’s health and reproductive medicine covers a wide range of areas. Mr. Angress serves as the scientific liaison for the company including principal investigator on Cicero’s SBIR NIH grants.
Dr. Lessey is the Scientific Advisor for Cicero Diagnostics, Inc. and is an internationally recognized leader in uterine receptivity research and the identification of markers associated with unexplained infertility. Dr. Lessey’s extensive research background includes published research on Beta 3 Integrin and BCL6, the two key components of the current ReceptivaDxTM Assay. He has served on multiple editorial boards for major journals and published over 150 peer reviewed articles, with a focus on infertility, endometriosis and the role of the endometrium in embryo implantation.
Dr. David Schammel is the lead pathologist for all ReceptivaDxTM testing for Cicero Diagnostics, Inc. . Dr. Schammel, a partner of Pathology Associates in Greenville, SC, has been involved with uterine receptivity testing for over 10 years. Dr. Schammel currently serves as the Medical Director for Pathology Consultants, Inc and is based at the main campus of the Greenville Health System in Greenville, SC.
Cicero Diagnostics currently holds the exclusive rights to market and sell the patent protected markers used in the ReceptivaDx™ testing platform. Patents are held by the University of North Carolina. Additional markers under research evaluation are also held as options by the company.
Cicero Diagnostics is currently involved with additional research studies having been awarded an SBIR Fast Track grant from the NIH in January of 2019. This 3 year grant allows Cicero to continue to validate what has currently been published on the biomarkers’ value in predicting endometriosis as the source of a women’s unexplained infertility. Other published papers have demonstrated the success of follow-up treatment leading to more live births for previously failed IVF patients. Using Wake Forest Medical Center, University of North Carolina, Clemson University and Stanford University, Cicero Diagnostics will conduct additional studies to supplement and support these findings.
Cicero currently uses three laboratory sites for our testing. Both sites have expertise in Anatomic pathology and specific expertise in these Immunohistochemistry bio-markers:
Please fill out the form below and we’ll contact you soon!
Customer Service Phone:
(800) 795-5385 or (657) 261-6740
Chris Jackson
Cjackson@cicerodx.com
Dan Angress
Dan@cicerodx.com
Email:
info@cicerodx.com
Corporate Office:
Cicero Diagnostics
2538 Anthem Village Drive #105
Henderson, NV 89052
